Imvax to Present New Data on Tumor-Derived Immunotherapy Platform at 2022 SITC Meeting

PHILADELPHIA--(BUSINESS WIRE)--Imvax, Inc., a clinical-stage biotechnology company developing personalized, whole tumor-derived immunotherapies, today announced two poster presentations at the 2022 Society for Immunotherapy of Cancer (SITC) Meeting in Boston, MA, from November 10-12, 2022.

At the meeting, Imvax will present data providing new insights into the mechanism of action of the company’s most advanced product candidate, IGV-001, for the treatment of glioblastoma. The company also will share in vivo data supporting the antitumor activity of Imvax’s tumor-derived immunotherapy platform for ovarian, liver and bladder cancers.

The details of the poster presentations are below:

Title: “Autologous tumor cell immunotherapeutic platform induces stress-correlated immunogenic cell death leading to immune activation within the draining lymph nodes”
Number: 1071
Timing: November 10, 2022, 9:00 am – 9:00 pm EST
Presenter: Christopher Cultrara, Ph.D.

Title: “Personalized immunotherapeutic platform, with evidence of clinical activity in glioblastoma, protects mice against ovarian, liver & bladder cancer tumor challenges”
Number: 1398
Timing: November 11, 2022, 9:00 am – 8:30 pm EST
Presenter: Amelia Zellander, Ph.D.

About Imvax, Inc.
Imvax is a clinical-stage biotechnology company with a unique platform technology focused on delivering personalized, whole tumor-derived immunotherapies across a range of solid tumors. Imvax’s portfolio includes several programs designed to stimulate a patient’s immune system against the full antigen signature of their tumor. Imvax’s most advanced program is IGV-001 for the treatment of glioblastoma. Imvax is headquartered in Philadelphia, PA. For additional information, please visit www.imvax.com.

Media:
Thomas Stephenson
Ten Bridge Communications
thomas@tenbridgecommunications.com
(857) 244-0246